article thumbnail

FDA Approves Susvimo for Diabetic Macular Edema

Drugs.com

Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic. WEDNESDAY, Feb. 5, 2025 -- The U.S.

article thumbnail

Novo says it’s submitted obesity pill for FDA approval

BioPharma Drive: Drug Pricing

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug Wegovy two years after reporting initial Phase 3 results.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novavax COVID Vaccine Moves Closer to Full FDA Approval

Drugs.com

FRIDAY, April 25, 2025 Novavaxs COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company said Wednesday.The update sent Novavaxs stock up more than 21% in early trading. It also helped ease.

article thumbnail

FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis

Drugs.com

Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without symptoms. The approval is the first for TAVR. MONDAY, May 5, 2025 -- The U.S.

article thumbnail

BioMarin finally secures FDA approval of hemophilia gene therapy

BioPharma Drive: Drug Pricing

After a prolonged journey, the medicine, known as Roctavian, is now cleared for certain patients with hemophilia A, the more common form of the rare bleeding disorder.

article thumbnail

Galderma wins FDA approval for skin condition treatment

BioPharma Drive: Drug Pricing

Nemluvio is now cleared for adults with the chronic itching condition prurigo nodularis, making it a competitor to Sanofi and Regeneron’s Dupixent.

article thumbnail

FDA Approves Dupixent for Chronic Spontaneous Urticaria

Drugs.com

Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.The approval is for patients 12 years and older who remain. WEDNESDAY, April 23, 2025 -- The U.S.